Eales Disease

National Organization for Rare Disorders, Inc.

Skip to the navigation


It is possible that the main title of the report Eales Disease is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.


  • Eales Retinopathy
  • Idiopathic Peripheral Periphlebitis

Disorder Subdivisions

  • None

General Discussion

Eales Disease is a rare disorder of sight that appears as an inflammation and white haze around the outercoat of the veins in the retina. The disorder is most prevalent among young males and normally affects both eyes. Usually, vision is suddenly blurred because the clear jelly that fills the eyeball behind the lens of the eye seeps out (vitreous hemorrhaging).


Eales Disease usually presents as blurred vision resulting from oozing of the clear jelly-like substance from behind the lens of the eye. At the onset of the disorder, the small outer veins of the retina show sheathing (encapsulation or covering). As the disease progresses, the inflammation around the veins in the retina extends further behind the lens. Eales Disease may also be associated with peripheral retinal neovascularization which is the formation of new blood vessels on the outer part of the retina.

The more advanced cases of Eales Disease are characterized by a non- inflammatory degenerative disease of the retina (retinopathy) and extensive bleeding in the retina. The colorless jelly that fills the eyeball behind the lens oozes from the retina (vitreous hemorrhage) and, in rare cases, the retina may become detached. A reddish discoloration of the iris may be present (rubeosis iridis), and there may be loss of vision and damage to the optic disk (neovascular glaucoma). Clouding of the lens of the eye that obstructs the passage of light (cataracts) may develop as the disease progresses.


The exact case of Eales Disease is not known. This disorder seems to occur spontaneously because no precipitating factors such as injury, infection, or heredity appear to be involved.

Affected Populations

Eales Disease is a rare disorder that affect males and females in equal numbers.

Standard Therapies

Treatment of Eales Disease is symptomatic and supportive. The surgical process of coagulating tissue with a laser beam (laser panretinal photocoagulation) may be used to eliminate the deficiency of blood in the retina caused by constriction of blood vessels and to slow down excessive formation of blood vessel tissue.

Hemorrhaging of the clear jelly that is behind the lens of the eye (vitreous) and detachment of the retina) may be helped by the removal of the dark pigmented disk and jelly-like substance behind the retina (pars plana vitrectomy.

Investigational Therapies

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government website.

For information about clinical trials being conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov

For information about clinical trials sponsored by private sources, contact:




Newell FW. Ophthalmology Principles and Concepts. 7th ed. St. Louis, MO: Mosby-Year Book Inc; 1992:300.


Sulochana KN, et al., Eales' disease: increased oxidation and peroxidation products of membrane constituents chiefly lipids and decreased antioxidant enzymes and reduced glutathione in vitreous. Curr Eye Res. 1999;19:254-59.

Shanmugam MP, et al., Long term visual results of vitrectomy for Eales disease complications. Int Ophthalmol. 1998;22:61-64.

Badrinath SS, et al., Vitreoschisis in Eales' disease: pathogenic role and significance in surgery. Retina. 1999;19:51-54.

Eller AW, et al., Peripheral retinal neovascularization (Eales disease) associated with the factor V Leiden mutation. Am J Ophthalmol. 1998;126:146-49.

Das T, et al., Eales' disease. Indian J Ophthalmol. 1994;42:3-18.


eMedicine - Eales Disease : Article by Daniel B Roth, MD


Rare Diseases Terms - Office of Rare Diseases



Schepens Eye Research Institute

20 Staniford Street

Boston, MA 02114-2500

Tel: (617)912-0100

Fax: (617)912-0101

Email: richard.godfrey@schepens.harvard.edu

Internet: http://www.theschepens.org/

NIH/National Eye Institute

31 Center Dr

MSC 2510

Bethesda, MD 20892-2510

United States

Tel: (301)496-5248

Fax: (301)402-1065

Email: 2020@nei.nih.gov

Internet: http://www.nei.nih.gov/

Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223

Internet: http://rarediseases.info.nih.gov/GARD/

For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.